TTUHSC School of Pharmacy
HomeSOPFaculty & Staff Directory

Faculty & Staff Details






Profile for Irene La-Beck, Pharm.D.

Ninh La-Beck

Irene La-Beck, Pharm.D.

  • Committee Chair
  • Committee Member
Office Phone: 325-696-0433
Email: irene.la-beck@ttuhsc.edu
Mail Address: 1718 Pine St
Abilene TX 79601-3044

Biography

I have a broad background in clinical pharmacology with specific training and expertise in anticancer nanoparticles. At the University of North Carolina (UNC), I used mouse models and clinical studies in cancer patients to investigate phenotypic probes of the mononuclear phagocyte system as biomarkers for personalizing therapy with anticancer liposomes. I also investigated the preclinical and clinical pharmacokinetics of novel anticancer nanoparticles such as Stealth liposomal CKD-602 (a camptothecin analogue), Optisomal topotecan, and folate-targeted polyethylene glycol- and gadolinium-PRINT (particle replication in non-wetting template)-nanoparticles. I joined the School of Pharmacy at TTUHSC as a new tenure-track assistant professor in September 2010 with the long-term goal of establishing a research program which is nationally/internationally recognized in the immuno-pharmacology of nanoparticles. My immediate research focus was on identifying novel immune mechanisms of resistance to anticancer nanoparticles. The overall goal of my research is to understand the consequences of the interactions between nanoparticles and the host immune system in order to develop novel strategies to maximize the efficacy of nanoparticle drugs.

Research Interests

nanoparticles
oncology
immunology
pharmacology

Selected Publications:

  • La-Beck I. The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials.. The Oncologist. 2013.
  • La-Beck I. Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology. Journal of Pharmacology and Experimental Therapeutics. 2013.
  • La-Beck I. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients.. Cancer Chemotherapy and Pharmacology. 2012;69(1):43-50.
  • La-Beck I. Renal Cell Carcinoma. McGraw-Hill Medical. 2011;(8).
  • La-Beck I. Carrier-Mediated and Targeted Cancer Drug Delivery. Springer Science. 2011;(1).
©